%0 Journal Article %1 Banerjee2006 %A Banerjee, K. J. %A Glasson, C. %A O'Flaherty, S. J. %D 2006 %J Dev Med Child Neurol %K Adolescent; Botulinum Tox; Cerebral Palsy; Child; Dose-Response Relationship, Drug; Female; Humans; Injections; Male; Neuromuscular Agents; Parotid Gland; Prospective Studies; Quality of Life; Sialorrhea; Submandibular Treatment Outcome; in Type A %N 11 %P 883--887 %R 10.1017/S0012162206001939 %T Parotid and submandibular botulinum toxin A injections for sialorrhoea in children with cerebral palsy. %U http://dx.doi.org/10.1017/S0012162206001939 %V 48 %X The aim of this study was to determine whether botulinum toxin A (BTX-A) injected into the parotid and submandibular salivary glands of children aged 6 to 16 years with cerebral palsy (CP) and relative sialorrhoea significantly decreases their drooling and improves their quality of life. Twenty children (10 males, 10 females; mean age 10y 1mo SD 3y 8mo; range 6y 1mo-16y 7mo) with CP, identified as having significant daily drooling (scoring at least 6 on drooling frequency/severity scales) were recruited. BTX-A (2U/kg; maximum 70U) was injected under sedation, using ultrasound guidance (1.4U/kg and 0.6U/kg divided between parotid and submandibular glands respectively). Nineteen children completed the study: 15 with spastic quadriplegia (Gross Motor Function Classification System GMFCS Level V); one with dystonia (GMFCS Level V); one with hemiplegia (GMFCS Level II); and two with a mixed pattern of CP (GMFCS Levels III and V). Drooling was assessed by five methods at baseline, and 4 and 12 weeks after injection. Qualitative assessment of drooling frequency and severity scores showed statistically significant reductions at 4 weeks (p<0.001) and 12 weeks (p=0.006). Qualitative assessment of quality of life scores (rated by parents and teachers separately) also significantly improved (p<0.001 and p=0.023 respectively). Quantitative assessments showed that the number of bibs/scarves changed per day was significantly reduced at 4 weeks (p<0.001). There was no side effect from the injections themselves; 89\% of parents and children wished for further intrasalivary BTX-A injections in the future. We conclude that percutaneous intrasalivary BTX-A injections into the parotid and submandibular salivary glands can reduce drooling in children with CP and relative sialorrhoea, leading to an improvement in their quality of life.

@article{Banerjee2006, abstract = {The aim of this study was to determine whether botulinum toxin A (BTX-A) injected into the parotid and submandibular salivary glands of children aged 6 to 16 years with cerebral palsy (CP) and relative sialorrhoea significantly decreases their drooling and improves their quality of life. Twenty children (10 males, 10 females; mean age 10y 1mo [SD 3y 8mo]; range 6y 1mo-16y 7mo) with CP, identified as having significant daily drooling (scoring at least 6 on drooling frequency/severity scales) were recruited. BTX-A (2U/kg; maximum 70U) was injected under sedation, using ultrasound guidance (1.4U/kg and 0.6U/kg divided between parotid and submandibular glands respectively). Nineteen children completed the study: 15 with spastic quadriplegia (Gross Motor Function Classification System [GMFCS] Level V); one with dystonia (GMFCS Level V); one with hemiplegia (GMFCS Level II); and two with a mixed pattern of CP (GMFCS Levels III and V). Drooling was assessed by five methods at baseline, and 4 and 12 weeks after injection. Qualitative assessment of drooling frequency and severity scores showed statistically significant reductions at 4 weeks (p<0.001) and 12 weeks (p=0.006). Qualitative assessment of quality of life scores (rated by parents and teachers separately) also significantly improved (p<0.001 and p=0.023 respectively). Quantitative assessments showed that the number of bibs/scarves changed per day was significantly reduced at 4 weeks (p<0.001). There was no side effect from the injections themselves; 89\% of parents and children wished for further intrasalivary BTX-A injections in the future. We conclude that percutaneous intrasalivary BTX-A injections into the parotid and submandibular salivary glands can reduce drooling in children with CP and relative sialorrhoea, leading to an improvement in their quality of life.}, added-at = {2014-07-19T17:53:25.000+0200}, author = {Banerjee, K. J. and Glasson, C. and O'Flaherty, S. J.}, biburl = {https://www.bibsonomy.org/bibtex/2e07030633e416618ef71d302f7310df6/ar0berts}, doi = {10.1017/S0012162206001939}, groups = {public}, interhash = {77b9a4f93f355892c8b54d68b6e6523b}, intrahash = {e07030633e416618ef71d302f7310df6}, journal = {Dev Med Child Neurol}, keywords = {Adolescent; Botulinum Tox; Cerebral Palsy; Child; Dose-Response Relationship, Drug; Female; Humans; Injections; Male; Neuromuscular Agents; Parotid Gland; Prospective Studies; Quality of Life; Sialorrhea; Submandibular Treatment Outcome; in Type A}, month = Nov, number = 11, pages = {883--887}, pii = {S0012162206001939}, pmid = {17044954}, timestamp = {2014-07-19T18:01:13.000+0200}, title = {Parotid and submandibular botulinum toxin A injections for sialorrhoea in children with cerebral palsy.}, url = {http://dx.doi.org/10.1017/S0012162206001939}, username = {ar0berts}, volume = 48, year = 2006 }